MYB is altered in 7.14% of pilomyxoid astrocytoma patients [3].

MYB is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is altered in 0.58% of diffuse glioma patients [3].

MYB is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is altered in 0.53% of astrocytic tumor patients [3].

MYB is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MYB status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is altered in 1.11% of low grade glioma patients [3].

MYB is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MYB status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYB status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MYB status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYB is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].